Atherosclerosis:Pentraxin-3与卒中预后无关

2015-11-08 phylis 译 MedSci原创

背景:脑卒中有着较高的致残率。评估疾病的严重程度和早期危险评估是非常重要的。许多研究正在进行,危险因素及卒中预后的评估的文献中,提出许多生物标志物。研究者旨在分析预测因子,比如患者年龄,性别,卒中体积及NIHSS分数等与卒中事件预后的相关性。研究者调查了血清pentraxin-3(PTX-3)与卒中预后的联系。方法:共有44名无心血管危险因素的卒中患者。在卒中发生第一天和第七天收集NIHSS,卒中

背景:脑卒中有着较高的致残率。评估疾病的严重程度和早期危险评估是非常重要的。许多研究正在进行,危险因素及卒中预后的评估的文献中,提出许多生物标志物。研究者旨在分析预测因子,比如患者年龄、性别、卒中体积及NIHSS分数等与卒中事件预后的相关性。研究者调查了血清pentraxin-3(PTX-3)与卒中预后的联系。

方法:共有44名无心血管危险因素的卒中患者。在卒中发生第一天和第七天收集NIHSS,卒中体积及血清PTX-3的水平及相关的危险因素的数据。应用多变量回归模型分析最后NIHSS分数和预测因子的相关性。

结果:最初的NIHSS,最初和最终的卒中体积与最终NIHSS相关,然而第一天和第七天的血清PTX-3水平与NHISS无关。

结论:无心血管疾病、心肺及感染疾病的卒中患者,血清PTX-3与卒中的预后无关。

原文出处:

Ceylan M, Yalcin A, Bayraktutan OF, et al. Serum pentraxin-3 levels in acute stroke: No association with stroke prognosis. Atherosclerosis. 2015, Nov 4.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1656680, encodeId=1d1c165668070, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Mar 24 12:11:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787076, encodeId=30581e87076e6, content=<a href='/topic/show?id=f61114032c6' target=_blank style='color:#2F92EE;'>#Pentraxin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14032, encryptionId=f61114032c6, topicName=Pentraxin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Oct 18 01:11:00 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947303, encodeId=a665194e303fa, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 15 03:11:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725919, encodeId=c5841e25919e5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 23 20:11:00 CST 2016, time=2016-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364070, encodeId=b78a13640e0f6, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Nov 10 13:11:00 CST 2015, time=2015-11-10, status=1, ipAttribution=)]
    2016-03-24 bsmagic9140
  2. [GetPortalCommentsPageByObjectIdResponse(id=1656680, encodeId=1d1c165668070, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Mar 24 12:11:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787076, encodeId=30581e87076e6, content=<a href='/topic/show?id=f61114032c6' target=_blank style='color:#2F92EE;'>#Pentraxin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14032, encryptionId=f61114032c6, topicName=Pentraxin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Oct 18 01:11:00 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947303, encodeId=a665194e303fa, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 15 03:11:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725919, encodeId=c5841e25919e5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 23 20:11:00 CST 2016, time=2016-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364070, encodeId=b78a13640e0f6, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Nov 10 13:11:00 CST 2015, time=2015-11-10, status=1, ipAttribution=)]
    2016-10-18 yzh399
  3. [GetPortalCommentsPageByObjectIdResponse(id=1656680, encodeId=1d1c165668070, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Mar 24 12:11:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787076, encodeId=30581e87076e6, content=<a href='/topic/show?id=f61114032c6' target=_blank style='color:#2F92EE;'>#Pentraxin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14032, encryptionId=f61114032c6, topicName=Pentraxin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Oct 18 01:11:00 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947303, encodeId=a665194e303fa, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 15 03:11:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725919, encodeId=c5841e25919e5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 23 20:11:00 CST 2016, time=2016-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364070, encodeId=b78a13640e0f6, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Nov 10 13:11:00 CST 2015, time=2015-11-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1656680, encodeId=1d1c165668070, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Mar 24 12:11:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787076, encodeId=30581e87076e6, content=<a href='/topic/show?id=f61114032c6' target=_blank style='color:#2F92EE;'>#Pentraxin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14032, encryptionId=f61114032c6, topicName=Pentraxin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Oct 18 01:11:00 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947303, encodeId=a665194e303fa, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 15 03:11:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725919, encodeId=c5841e25919e5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 23 20:11:00 CST 2016, time=2016-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364070, encodeId=b78a13640e0f6, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Nov 10 13:11:00 CST 2015, time=2015-11-10, status=1, ipAttribution=)]
    2016-08-23 feather89
  5. [GetPortalCommentsPageByObjectIdResponse(id=1656680, encodeId=1d1c165668070, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Mar 24 12:11:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787076, encodeId=30581e87076e6, content=<a href='/topic/show?id=f61114032c6' target=_blank style='color:#2F92EE;'>#Pentraxin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14032, encryptionId=f61114032c6, topicName=Pentraxin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=310e209, createdName=yzh399, createdTime=Tue Oct 18 01:11:00 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947303, encodeId=a665194e303fa, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 15 03:11:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725919, encodeId=c5841e25919e5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Aug 23 20:11:00 CST 2016, time=2016-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364070, encodeId=b78a13640e0f6, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Tue Nov 10 13:11:00 CST 2015, time=2015-11-10, status=1, ipAttribution=)]
    2015-11-10 lsndxfj

相关资讯

Neurology:导致腔隙性卒中患者发生血管事件的潜在因素

本研究开展了一项小皮层下卒中(SPS3)队列研究的二级预防前瞻性研究,检测了代谢综合征和糖尿病导致卒中复发的风险。 SPS3试验收纳了3020名腔隙性卒中患者。根据美国心脏协会/国家心脏、肺和血液研究所以及世界卫生组织的指南将参与者分成代谢综合征组,糖尿病组,代谢综合征和糖尿病组以及对照组。对卒中、心肌梗死和全因死亡率以及风险比(HRs)进行评估,并将结果与基线处对比。 在2999名参与者中,

Int J Cardiol:外周动脉疾病和房颤是卒中、心衰及心血管死亡的独立危险因素

背景:外周动脉疾病(PAD)和心房颤动(AF)存在许多共同并发病,并且导致相同的心血管(CV)预后。只有少数的研究评估PAD,AF,及对CV预后的影响的相关性。方法:研究者选取来自台湾国家健康保险研究数据库的597164名成年人进行一项队列研究,以评估PAD是否是房颤的独立危险因素,房颤是否是PAD的独立危险因素。研究者确定PAD和房颤是否增加卒中的发生,心脏衰竭住院及心血管死亡。结果:存在PAD

Psychiatry Res:低血清白蛋白与老年人长期卒中后抑郁症状相关

背景:大约有三分之一的卒中幸存者存在卒中后抑郁。非卒中人群中,抑郁症状与低蛋白血症相关。这在卒中幸存者中比较常见,并且与不良预后和死亡率增高相关。卒中相关性低蛋白血症在卒中后抑郁中的作用尚不清楚。研究者旨在探索卒中发生20月后,血清白蛋白和卒中后抑郁的相关性。方法:从“瑞典哥德堡70 +卒中研究”中选取老年瑞典患者(n = 149)进行观察性队列研究,卒中后20个月进行评估。抽取静脉血并应用气相色

Stroke:年轻人更应该谨防空气污染给我们带来的卒中风险!

研究已经证实心血管疾病和颗粒物(PM)<10和<2.5μm直径之间有一致的联系,但卒中却很少受到关注。研究人员假设,空气污染,炎症引发因子,可能与那些常见脑卒中的危险因素不太常见的的年轻患者中脑卒中发病率有关联。该研究的目的是评估中风的发病率和暴露于PM<10和<2.5μm颗粒物之间的关联,在一个特点是PM范围广泛的沙漠地区进行。该研究包括了以色列最大的健康维护组织的全体成

Stroke:阵发性房颤不增加卒中的风险

背景和目的:房颤(AF)类型和卒中的关系存在争议。尽管许多研究表明阵发性AF(PAF)和持续性或永久性房颤与卒中发生的风险一致,最近研究表明PAF与卒中发生风险较低相关。在亚洲人群众PAF与卒中风险之间的相关性数据也是非常有限的。方法:日本一项基于社区的房颤患者的调查研究,将房颤分为两类:PAF或持续性房颤。研究者比较PAF(n=1588)和持续性房颤(n=1716)临床事件的发生。结果:一般情况

J Epidemiol:睡眠时间短,卒中死亡率低

背景:评估睡眠时间和卒中亚型之间的关系的研究较少。研究者进行了一项以日本男性和女性人群中,评估睡眠时间是否与总卒中、缺血性卒中和出血性卒中死亡率相关。方法:共有12875名男性和15021名女性受试者,在1992年时,年龄大于等于35岁。对受试者进行随访至2008年。预后变量为卒中死亡(缺血性中风、出血性中风和各种卒中)。结果:在随访期间,611名发生卒中死亡(354例缺血性卒中,217例出血性卒